Skadden Advises Endo On $1.2B Qualitest Purchase

Law360, New York (September 28, 2010, 7:31 PM EDT) -- Endo Pharmaceuticals said Tuesday it has agreed to buy privately held generic drug company Qualitest Pharmaceuticals in a $1.2 billion deal that will expand its offerings in pain management drugs.

The Chadds Ford, Pa.-based company will acquire 100 percent of Qualitest, the sixth-largest generics maker in the U.S. by prescriptions filled, for $1.2 billion in cash from private equity group Apax Partners.

It will fund the purchase with $500 million in cash from its balance sheet, drawing down an existing $300 million revolving credit facility, and...
To view the full article, register now.